AAOMS Annual Meeting

The FDA has approved a new, daily, fixed-dose combination therapy for HIV treatment, and a new add-on treatment for severe, poorly-controlled asthma.

The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.

The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.

The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.

The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.

The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.

The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.

The FDA has approved new options for schizophrenia and non-small cell lung cancer, as well as a cerebrospinal fluid test for the detection of various pathogens.

The FDA has approved 2 new drugs for the improvement of blood glucose control in patients with type 1 and type 2 diabetes mellitus.

The FDA has approved 2 new drugs for the improvement of blood glucose control in patients with type 1 and type 2 diabetes mellitus.